Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures

We aimed to describe the extent of neurodevelopmental impairments and identify the genetic etiologies in a large cohort of patients with epilepsy with myoclonic atonic seizures (MAE).

[1]  R. Nabbout,et al.  Exome sequencing findings in 27 patients with myoclonic‐atonic epilepsy: Is there a major genetic factor? , 2019, Clinical genetics.

[2]  Kenneth D. Mandl,et al.  A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy. , 2019, American journal of human genetics.

[3]  J. Hentschel,et al.  Parental mosaicism in epilepsies due to alleged de novo variants , 2019, Epilepsia.

[4]  Charuta N. Joshi,et al.  Diagnosis switching and outcomes in a cohort of patients with potential epilepsy with myoclonic-atonic seizures , 2018, Epilepsy Research.

[5]  M. Daly,et al.  De novo variants in neurodevelopmental disorders with epilepsy , 2018, Nature Genetics.

[6]  Ethan M. Goldberg,et al.  Neurodevelopmental Disorders Caused by De Novo Variants in KCNB1 Genotypes and Phenotypes , 2017, JAMA neurology.

[7]  L. Lagae,et al.  Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders , 2017, Brain : a journal of neurology.

[8]  Bradley P. Coe,et al.  Targeted sequencing identifies 91 neurodevelopmental disorder risk genes with autism and developmental disability biases , 2017, Nature Genetics.

[9]  C. Barba,et al.  Diagnostic Targeted Resequencing in 349 Patients with Drug‐Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes , 2017, Human mutation.

[10]  Ingo Borggraefe,et al.  Mutations in GABRB3: From febrile seizures to epileptic encephalopathies , 2017, Neurology.

[11]  L. Villard.  Faculty Opinions recommendation of Mutations in GABRB3: From febrile seizures to epileptic encephalopathies. , 2017 .

[12]  J. Rosenfeld,et al.  De Novo Mutations in CHD4, an ATP-Dependent Chromatin Remodeler Gene, Cause an Intellectual Disability Syndrome with Distinctive Dysmorphisms. , 2016, American journal of human genetics.

[13]  M. Simpson,et al.  New SMARCA2 mutation in a patient with Nicolaides–Baraitser syndrome and myoclonic astatic epilepsy , 2016, American journal of medical genetics. Part A.

[14]  J. Rosenfeld,et al.  TBC1D24 genotype–phenotype correlation , 2016, Neurology.

[15]  Orrin Devinsky,et al.  De novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy , 2016, Journal of Medical Genetics.

[16]  Sanxiong Liu,et al.  Histone methyltransferase Ash1L mediates activity-dependent repression of neurexin-1α , 2016, Scientific Reports.

[17]  H. Mefford,et al.  Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy , 2016, Journal of Medical Genetics.

[18]  Naomichi Matsumoto,et al.  De novo KCNB1 mutations in infantile epilepsy inhibit repetitive neuronal firing , 2015, Scientific Reports.

[19]  G. Carvill,et al.  Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. , 2015, American journal of human genetics.

[20]  Maja Steinlin,et al.  De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy , 2015, Nature Genetics.

[21]  Tomas W. Fitzgerald,et al.  Large-scale discovery of novel genetic causes of developmental disorders , 2014, Nature.

[22]  J. Roach,et al.  Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes , 2014, Nature Genetics.

[23]  Soyong Eom,et al.  Routine developmental, autism, behavioral, and psychological screening in epilepsy care settings , 2014, Developmental medicine and child neurology.

[24]  Christopher S. Poultney,et al.  Synaptic, transcriptional, and chromatin genes disrupted in autism , 2014, Nature.

[25]  Edouard Henrion,et al.  De Novo Mutations in Moderate or Severe Intellectual Disability , 2014, PLoS genetics.

[26]  T. Fujita,et al.  Early onset and focal spike discharges as indicators of poor prognosis for myoclonic-astatic epilepsy , 2014, Brain and Development.

[27]  Holger Lerche,et al.  De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. , 2013, American journal of human genetics.

[28]  Michael R. Johnson,et al.  De novo mutations in the classic epileptic encephalopathies , 2013, Nature.

[29]  J. Shendure,et al.  Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1 , 2013, Nature Genetics.

[30]  H. Arroyo,et al.  Epilepsy with myoclonic atonic seizures: an electroclinical study of 69 patients. , 2013, Pediatric neurology.

[31]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[32]  D. Horn,et al.  Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study , 2012, The Lancet.

[33]  Evan T. Geller,et al.  Patterns and rates of exonic de novo mutations in autism spectrum disorders , 2012, Nature.

[34]  Michael F. Walker,et al.  De novo mutations revealed by whole-exome sequencing are strongly associated with autism , 2012, Nature.

[35]  Bradley P. Coe,et al.  Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations , 2012, Nature.

[36]  I. Scheffer,et al.  Rare copy number variants are an important cause of epileptic encephalopathies , 2011, Annals of neurology.

[37]  F. Vigevano,et al.  Myoclonic astatic epilepsy: An age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution , 2011, Epilepsy Research.

[38]  Kate M. Lawrence,et al.  Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. , 2011, Archives of neurology.

[39]  Ulrich Stephani,et al.  Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in Idiopathic Generalized and Focal Epilepsies , 2010, PLoS genetics.

[40]  J. H. Cross,et al.  Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009 , 2010, Epilepsia.

[41]  A. Bergqvist,et al.  Current Treatment of Myoclonic Astatic Epilepsy: Clinical Experience at the Children's Hospital of Philadelphia , 2007, Epilepsia.

[42]  A. Brice,et al.  Absence of mutations in major GEFS+ genes in myoclonic astatic epilepsy , 2003, Epilepsy Research.

[43]  H. Meltzer,et al.  Mental health of children and adolescents in Great Britain , 2003, International review of psychiatry.

[44]  M. Funatsuka,et al.  Treatment and Long-Term Prognosis of Myoclonic-Astatic Epilepsy of Early Childhood , 2002, Neuropediatrics.

[45]  M. Funatsuka,et al.  Myoclonic–astatic epilepsy of early childhood – clinical and EEG analysis of myoclonic–astatic seizures, and discussions on the nosology of the syndrome , 2001, Brain and Development.

[46]  A. Heils,et al.  A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy. , 2001, American journal of human genetics.

[47]  G. Dellatolas,et al.  Delineation of cryptogenic Lennox–Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis , 1999, Epilepsy Research.

[48]  Samuel F. Berkovic,et al.  Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel ß1 subunit gene SCN1B , 1998, Nature Genetics.

[49]  T. Kurashige,et al.  Proposal for Revised Classification of Epilepsies and Epileptic Syndromes , 1989, No to hattatsu = Brain and development.

[50]  H. Doose,et al.  Centrencephalic Myoclonic-Astatic Petit Mal1 – Clinical and genetic investigations , 1970, Neuropadiatrie.

[51]  M. Wolff,et al.  Behavioural and developmental aspects of primary generalized myoclonic-astatic epilepsy. , 1992, Epilepsy research. Supplement.